These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9684930)

  • 1. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
    Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
    Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
    Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
    Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
    Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
    Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
    Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
    Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
    J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
    Uckun FM; Evans WE; Forsyth CJ; Waddick KG; Ahlgren LT; Chelstrom LM; Burkhardt A; Bolen J; Myers DE
    Science; 1995 Feb; 267(5199):886-91. PubMed ID: 7531365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
    Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
    Myers DE; Jun X; Clementson D; Donelson R; Sicheneder A; Hoffman N; Bell K; Sarquis M; Langlie MC; Turner N; Uckun FM
    Leuk Lymphoma; 1997 Oct; 27(3-4):275-302. PubMed ID: 9402326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
    Myers DE; Irvin JD; Smith RS; Kuebelbeck VM; Uckun FM
    J Immunol Methods; 1991 Feb; 136(2):221-37. PubMed ID: 1705571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
    Uckun FM; Jaszcz W; Ambrus JL; Fauci AS; Gajl-Peczalska K; Song CW; Wick MR; Myers DE; Waddick K; Ledbetter JA
    Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of CD19+ leukemia by targeted calicheamicin θ.
    Bernt KM; Prokop A; Huebener N; Gaedicke G; Wrasidlo W; Lode HN
    Bioconjug Chem; 2009 Aug; 20(8):1587-94. PubMed ID: 19572629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
    Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
    Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
    J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
    Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy.
    Li Q; Hudson W; Wang D; Berven E; Uckun FM; Kersey JH
    Cancer Immunol Immunother; 1998 Nov; 47(3):121-30. PubMed ID: 9829837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
    Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeted killing of the Nalm-6 cells with 2E8-Genistein immunotoxin and its mechanism].
    Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):57-61. PubMed ID: 19573385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia.
    Uckun FM; Qazi S; Dibirdik I; Myers DE
    Integr Biol (Camb); 2013 Jan; 5(1):122-32. PubMed ID: 22990208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer therapeutic potential of soy isoflavone, genistein.
    Ravindranath MH; Muthugounder S; Presser N; Viswanathan S
    Adv Exp Med Biol; 2004; 546():121-65. PubMed ID: 15584372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.